Stock comparison
JOHNSON & JOHNSON is 1.4x more valuable than AbbVie Inc. by market capitalization ($622.64 B vs $440.14 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
JNJ is larger
JOHNSON & JOHNSON is 1.4x more valuable than AbbVie Inc. by market capitalization ($622.64 B vs $440.14 B).
Market value leader
JNJ
JOHNSON & JOHNSON is 1.4x more valuable than AbbVie Inc. by market capitalization ($622.64 B vs $440.14 B).
Revenue leader
JNJ
ABBV: $61.16B vs JNJ: $94.19B.
Profit leader
JNJ
ABBV: $4.23B vs JNJ: $26.80B.
Margin leader
JNJ
ABBV: 6.9% vs JNJ: 28.5% net margin.
| Metric | ABBV | JNJ |
|---|---|---|
| Market cap | $440.14 B | $622.64 B |
| US-listed rank | #25 | #18 |
| Revenue (latest FY) | $61.16B | $94.19B |
| Net income (latest FY) | $4.23B | $26.80B |
| Net margin | 6.9% | 28.5% |
| P/E (trailing FY) | 104.2x | 23.2x |
| SEC filings | 1,008 | 990 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
JOHNSON & JOHNSON is 1.4x more valuable than AbbVie Inc. by market capitalization ($622.64 B vs $440.14 B).
In their latest fiscal years, AbbVie Inc. reported $61.16B in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: AbbVie Inc. and JOHNSON & JOHNSON, or browse the full rankings.